Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy

AIDS

Volumn 27, Issue 4, 2013, Pages 635-643

  Lacombe, Jean Marc ^a   Boue, François ^b   Grabar, Sophie ^a   Viget, Nathalie ^c   Gazaignes, Sandrine ^d   Lascaux Cametz, Anne Sophie ^e   Pacanowski, Jérome ^f   Partisani, Marialuisa ^g   Launay, Odile ^h   Matheron, Sophie ^h   Rosenthal, Eric ⁱ   Rouveix, Elisabeth ^j   Tattevin, Pierre ^k   De Truchis, Pierre ^l   Costagliola, Dominique ^a   Goedert, James J ^m  

^a INSERM   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE HOSPITALIER DE TOURCOING   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j HÔPITAL AMBROISE PARÉ   (France)

^k PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^l RAYMOND POINCARÉ HOSPITAL   (France)

^m NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

combination antiretroviral therapy; immune reconstitution inflammatory syndrome; Kaposi sarcoma; Pneumocystis jiroveci pneumonia; prospective cohort study

Indexed keywords

COTRIMOXAZOLE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; INCIDENCE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV SEROPOSITIVITY; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; PROSPECTIVE STUDIES; RISK FACTORS; SARCOMA, KAPOSI; TIME FACTORS; VIRAL LOAD;

EID: 84873408510     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cba6c     Document Type: Article

References (32)

1. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627.
2. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251-261.
3. Shelburne SA3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213-227.
4. Leidner RS, Aboulafia DM. Recrudescent Kaposís sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19:635-644.
5. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, et al. Immune reconstitution inflammatory syndrome associated with Kaposís sarcoma. J Clin Oncol 2005; 23:5224-5228.
6. Letang E, Almeida JM, MiroJM, Ayala E,White IE,Carrilho C, et al. Predictors of immune reconstitution inflammatory syndromeassociated with kaposi sarcoma in mozambique: a prospective study. J Acquir Immune Defic Syndr 2010; 53:589-597.
7. Connick E, Kane MA, White IE, Ryder J, Campbell TB. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004; 39:1852-1855.
8. Feller L, Anagnostopoulos C, Wood NH, Bouckaert M, Raubenheimer EJ, Lemmer J. Human immunodeficiency virusassociated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report. J Periodontol 2008; 79:362-368.
9. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012; 54:424-433.
10. Moore PS, Chang Y. Kaposís sarcoma (KS), KS-associated herpesvirus, and the criteria for causality in the age of molecular biology. Am J Epidemiol 1998; 147:217-221.
11. Engels EA, Biggar RJ, Marshall VA, Walters MA, Gamache CJ, Whitby D, et al. Detection and quantification of Kaposís sarcoma-associated herpesvirus to predict AIDS-associated Kaposís sarcoma. AIDS 2003; 17:1847-1851.
12. Mahnke YD, Greenwald JH, Dersimonian R, Roby G, Antonelli LR, Sher A, et al. Selective expansion of polyfunctional pathogen- specific CD4R T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012; 119:3105-3112.
13. Novak RM, Richardson JT, Buchacz K, Chmiel JS, Durham MD, Palella FJ, et al. Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 2012; 26:721-730.
14. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601-610.
15. Porter BO, Ouedraogo GL, Hodge JN, Smith MA, Pau A, Roby G, et al. D-dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Clin Immunol 2010; 136:42-50.
16. Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR. Immune reconstitution and risk of Kaposi sarcoma and non- Hodgkin lymphoma in HIV-infected adults. AIDS 2011; 25:1395-1403.
17. Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800-804.
18. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
19. WuH, Ding AA. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 1999; 55:410-418.
20. Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31:20-26.
21. Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud E, et al. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 1999; 13:1881-1887.
22. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341:441.
23. WHO. ICD-9: International Statistical Classification of Diseases (Revision 1995). Geneva: World Health Organization; 1977.
24. WHO. ICD-10: International Statistical Classification of Diseases and Related Health Problems. Geneva: World Health Organization; 1993.
25. Grant PM, Komarow L, Andersen J, Sereti I, Pahwa S, Lederman MM, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010; 5:e11416.
26. Antonelli LR, Mahnke Y, Hodge JN, Porter BO, Barber DL, DerSimonian R, et al. Elevated frequencies of highly activated CD4R T cells in HIVR patients developing immune reconstitution inflammatory syndrome. Blood 2010; 116:3818-3827.
27. Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev 2009; 22:651-663.
28. Flores R, Goedert JJ. Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus. AIDS 2010; 24:2279-2281.
29. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposís sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94:1204-1210.
30. O'Brien TR, Kedes D, Ganem D, Macrae DR, Rosenberg PS, Molden J, et al. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposís sarcoma. J Infect Dis 1999; 180:1010- 1017.
31. O'Brien TR, Engels EA, Rosenberg PS, Goedert JJ. Relationship between Kaposi sarcoma-associated herpesvirus and HIV. JAMA 2002; 287:1525-1526.
32. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst 2010; 102:784-792.